Compare GOSS & HOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GOSS | HOV |
|---|---|---|
| Founded | 2015 | 1959 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 726.8M | 591.8M |
| IPO Year | 2019 | N/A |
| Metric | GOSS | HOV |
|---|---|---|
| Price | $3.57 | $101.60 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 1 |
| Target Price | $8.60 | ★ $120.00 |
| AVG Volume (30 Days) | ★ 3.3M | 128.4K |
| Earning Date | 11-05-2025 | 12-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 7.43 |
| Revenue | $44,051,000.00 | ★ $2,978,581,000.00 |
| Revenue This Year | N/A | $7.30 |
| Revenue Next Year | $6.41 | $4.88 |
| P/E Ratio | ★ N/A | $14.27 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.76 | $81.15 |
| 52 Week High | $3.87 | $162.06 |
| Indicator | GOSS | HOV |
|---|---|---|
| Relative Strength Index (RSI) | 56.81 | 38.93 |
| Support Level | $3.53 | $104.84 |
| Resistance Level | $3.87 | $110.17 |
| Average True Range (ATR) | 0.24 | 6.41 |
| MACD | -0.02 | -0.33 |
| Stochastic Oscillator | 51.96 | 17.43 |
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
Hovnanian Enterprises Inc conducts all of its homebuilding and financial services operations . The company designs, constructs, markets, and sells single-family detached homes, attached townhomes and condominiums, urban infill, and active lifestyle homes in planned residential developments. It has two distinct operations: homebuilding and financial services. Its homebuilding operations are divided geographically into three segments; Northeast which includes Delaware, Maryland, New Jersey, Ohio, Pennsylvania, Virginia and West Virginia; Southeast which includes Florida, Georgia and South Carolina; and West which includes Arizona, California and Texas. The firm generates maximum revenue from West Segment.